COVID-19 in familial Mediterranean fever: Clinical course and complications related to primary disease

Avanoglu Guler et al., Modern Rheumatology, doi:10.1093/mr/roac074

Jul 2022

Source PDF All Studies Meta AnalysisMeta

Retrospective 73 familial Mediterranean fever patients with COVID-19 in Turkey, showing significantly higher risk of hospitalization for respiratory support with non-adherence to colchicine treatment before the infection.

Important missing comments or errors? Let us know.

risk of oxygen therapy, 78.8% lower, RR 0.21, p = 0.04, treatment 6 of 66 (9.1%), control 3 of 7 (42.9%), NNT 3.0, inverted to make RR<1 favor treatment, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Avanoglu Guler et al., 21 Jul 2022, retrospective, Turkey, peer-reviewed, median age 39.5, 14 authors.

Contact: aslihanavanoglu@gmail.com.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Colchicine All

COVID-19 in familial Mediterranean fever: Clinical course and complications related to primary disease

Aslihan Avanoglu Guler, Tuba Yuce Inel, Timucin Kasifoglu, Cansu Coskun, Hazan Karadeniz, Derya Yildirim, Reyhan Bilici, Hasan Satis, Hamit Kucuk, Seminur Haznedaroglu, Berna Goker, Mehmet Akif Ozturk, Ismail Sari, Abdurrahman Tufan

Modern Rheumatology, doi:10.1093/mr/roac074

Objectives: To evaluate the impact of familial Mediterranean fever (FMF) features on the clinical course and outcomes of coronavirus disease 2019 (COVID-19) and clinical course of FMF after COVID-19. Methods: Consecutive FMF patients with COVID-19 were enrolled from three referral hospitals. Clinical features of FMF and detailed COVID-19 information were obtained from patient interviews and medical records. Results: Seventy-three FMF patients were included in the study. 94.5% of patients had clinical symptoms of COVID-19. We found 24.7% hospitalization, 12.3% respiratory support, 4.1% intensive care unit admission, 6.8% complication, and 1.4% mortality rate in patients. The risk factors of hospitalization for respiratory support were male gender [OR: 7.167 (95% CI: 1.368-37.535)], greater age [OR: 1.067 (95% CI: 1.016-1.121)], and non-adherence to colchicine treatment before the infection [OR: 7.5 (95% CI: 1.348-41.722)]. One-third of patients had reported attacks after COVID-19. The patterns of triggered attacks were fever, peritonitis, pleuritis, transient arthritis, chronic knee mono-arthritis, and protracted febrile myalgia. Conclusions: FMF characteristics were not associated with worse outcomes of COVID-19. Colchicine non-adherence was the risk factor of hospitalization for oxygen support. The rate of FMF attacks after COVID-19 is prominently increased, with some of them being protracted and destructive.

Conflict of interest None declared. Ethics approval and consent to participate and for publication This study was approved by the Ministry of Health and Gazi University Hospital Ethics Committee (protocol number: 322, 29/03/2021) and followed the guidelines from Helsinki Declaration. All patients signed the informed consent, including consent for publication.

References

Bourguiba, Delplanque, Vinit, Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218707

Esatoglu, Tascilar, Babao G Lu, COVID-19 among patients with inflammatory rheumatic diseases, Front Immunol, doi:10.3389/fimmu.2021.651715

Freeman, Swartz, Targeting the NLRP3 inflammasome in severe COVID-19, Front Immunol, doi:10.3389/fimmu.2020.01518

Gao, Ding, Dong, Risk factors for severe and critically ill COVID-19 patients: a review, Allergy, doi:10.1111/all.14657

Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032

Gustine, Jones, Immunopathology of hyperinflammation in COVID-19, Am J Pathol, doi:10.1016/j.ajpath.2020.08.009

Günendi, Yurdakul, Bodur, The impact of COVID-19 on familial Mediterranean fever: a nationwide study, Rheumatol Int, doi:10.1007/s00296-021-04892-6

Güven, Erden, Karaka S Ö, COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study, Rheumatol Int, doi:10.1007/s00296-021-04812-8

Henderson, Canna, Schulert, On the alert for cytokine storm: immunopathology in COVID-19, Arthritis Rheumatol, doi:10.1002/art.41285

Huang, Wang, Li, features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/s0140-6736(20)30183-5

Issa, Merhi, Panossian, SARS-CoV-2 and ORF3a: nonsynonymous mutations, functional domains, and viral pathogenesis, mSystems, doi:10.1128/mSystems.00266-20

Kharouf, Ishay, Kenig, Incidence and course of COVID-19 hospitalisations among patients with familial Mediterranean fever, Rheumatology, doi:10.1093/rheumatology/keab577

Kow, Lee, Ramachandram, The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: a meta-analysis of randomised trials, Immun Inflamm Dis, doi:10.1002/iid3.562

Kukuy, Beckerman, Dinour, Amyloid storm: acute kidney injury and massive proteinuria, rapidly progressing to end-stage kidney disease in AA amyloidosis of familial Mediterranean fever, Rheumatology, doi:10.1093/rheumatology/keaa772

Leung, Hui, Kraus, Colchicine-update on mechanisms of action and therapeutic uses, Semin Arthritis Rheum, doi:10.1016/j.semarthrit.2015.06.013

Livneh, Langevitz, Zemer, Criteria for the diagnosis of familial Mediterranean fever, Arthritis Rheum, doi:10.1002/art.1780401023

Qin, Zhou, Hu, Dysregulation of Immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China, Clin Infect Dis, doi:10.1093/cid/ciaa248

Schultze, Aschenbrenner, COVID-19 and the human innate immune system, Cell, doi:10.1016/j.cell.2021.02.029

Stella, Lamkanfi, Portincasa, Familial Mediterranean fever and COVID-19: friends or foes?, Front Immunol, doi:10.3389/fimmu.2020.574593

Strangfeld, Sch Ä Fer, Gianfrancesco, Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219498

Tufan, Lachmann, Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review, Turk J Med Sci, doi:10.3906/sag-2008-11

Tufan, Matucci-Cerinic, Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation, Turk J Med Sci, doi:10.3906/sag-2110-179

Wang, Hu, Hu, Clinical characteristics of 138 hospitalised patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585

Xu, Shi, Wang, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med, doi:10.1016/s2213-2600(20)30076-x

Yang, Shen, Li, Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19, J Allergy Clin Immunol, doi:10.1016/j.jaci.2020.04.027

Özen, Sag, Ben-Chetrit, Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach, Rheumatology, doi:10.1093/rheumatology/keaa863

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0